All-trans retinoic acid (atRA), the main biologically active metabolite of vitamin A, has been implicated in immunoregulation and anti-cancer. A recent finding that vitamin A could decrease the risk of melanoma in humans indicates the beneficial role of atRA in melanoma. However, it remains unknown whether topical application of atRA could inhibit melanoma growth by influencing tumour immunity. We demonstrate topical application of tretinoin ointment (atRA as the active ingredient) effectively inhibited B16F10 melanoma growth. This is accompanied by markedly enhanced CD8 + T-cell responses, as evidenced by significantly increased proportions of effector CD8 + T cells expressing granzyme B, tumour necrosis factor-a, or interferon-c, and Ki67 + proliferating CD8 + T cells in atRA-treated tumours compared with vaseline controls. Furthermore, topical atRA treatment promoted the differentiation of effector CD8 + T cells in draining lymph nodes (DLN) of tumour-bearing mice.
Summary
All-trans retinoic acid (atRA), the main biologically active metabolite of vitamin A, has been implicated in immunoregulation and anti-cancer. A recent finding that vitamin A could decrease the risk of melanoma in humans indicates the beneficial role of atRA in melanoma. However, it remains unknown whether topical application of atRA could inhibit melanoma growth by influencing tumour immunity. We demonstrate topical application of tretinoin ointment (atRA as the active ingredient) effectively inhibited B16F10 melanoma growth. This is accompanied by markedly enhanced CD8 + 
Introduction
Malignant melanoma is the most aggressive type of skin cancer, accounting for 90% of skin cancer mortality, and has been recognized as one of the most immunogenic malignancies with abundant infiltration of various immune cells. 1 The types and activation status of immune cells have great impacts on the progression of melanoma and the responsiveness to immunotherapy. 2, 3 Cytotoxic CD8 + T cells are well-known to play a crucial antitumour role in melanoma, primarily through the release of cytotoxic mediators such as granzymes and interferonc (IFN-c) upon the recognition of MHCI molecule-associated tumour antigens, 4 whereas CD4 + T cells with different functional subsets play a complex role in melanoma, for example, IFN-c-producing T helper type 1 (Th1) cells and Foxp3 + regulatory T (Treg) cells play anti-tumour and pro-tumour roles, respectively. 5, 6 In addition, tumour infiltrating myeloid cells including macrophages and myeloid-derived suppressor cells
I M M U N O L O G Y O R I G I N A L A R T I C L E
(MDSCs) could suppress anti-tumour T-cell immunity via various mechanisms, thereby leading to tumour immune escape and less responsiveness to immunotherapy. 7, 8 Vitamin A and its main biologically active metabolite all-trans retinoic acid (atRA) have been extensively studied to determine their role in immunoregulation and anti-cancer. 9, 10 AtRA is known to influence both CD4 + and CD8 + T cells by regulating the migration, differentiation and activation under different conditions. 11 Accumulating evidence suggests a critical role of atRA in mucosal tolerance by imprinting the homing of CD4 + T cells to the gut and enhances the induction of regulator T cells while reciprocally inhibiting the development of Th17 cells in the intestinal lamina propria. 12, 13 On the other hand, atRA was reported to promote effector T-cell responses under some inflammatory conditions. For example, conditional ablation of atRA signalling in CD4 + T cells suppressed the inflammatory responses that mediate the rejection of allogeneic skin grafts, 14 and genetic or pharmacological manipulation of the atRA-RARa axis influenced effector functions of Th1, Th17 cells and CD8 + T cells in response to infection. 9, [15] [16] [17] Additionally, atRA has been shown to induce the differentiation of immature myeloid cells, which directly promoted T-cellmediated tumour-specific immune responses, leading to improved effect of cancer vaccines. 18, 19 AtRA is also a well-known anti-cancer drug that is used clinically to treat leukaemia 20 and pre-clinically for the treatment of a number of types of cancer including hepatoma and breast cancer. 21, 22 Most studies have been focused on the direct effect of atRA on the apoptosis and differentiation of tumour cells; however, little is known about the contribution of the immunoregulatory effect of atRA to its anticancer role.
A recent study showed that taking vitamin A supplements may be able to decrease the risk of developing melanoma, 23 suggesting a beneficial effect of atRA in melanoma. Most previous studies focused on the direct inhibitory effect of atRA on the biology of melanoma cells in vitro. [24] [25] [26] There are only two studies focusing on the immunoregulatory role of atRA in melanoma, showing the opposing effect. Guo et al. 27 demonstrated that genetic interruption of RARa, the primary functional receptor of atRA, in CD8 + T cells aggravated B16F10 tumour growth in CD4-depleted mice. In contrast, Galvin et al. 28 reported that treatment with a RARa inhibitor enhanced the protective efficacy of a DC vaccine against B16F10 tumours by suppressing the induction of Treg cells and promoting Th1 responses. It is noted that both experiments studied the role of endogenous atRA signalling in melanoma, and accumulating data indicate that atRA at physiological or pharmacological concentrations could have opposing effects on T-cell immunity. [29] [30] [31] We therefore aimed to investigate whether topical application of atRA was able to inhibit the established melanoma and the underlying immunological mechanism.
In this study, our results demonstrated that topical application of tretinoin ointment (with atRA as the active ingredient) effectively inhibited B16F10 melanoma growth in vivo, which was partly dependent on its ability to promote anti-tumour CD8 + T-cell immunity.
Materials and methods

Mice and cell lines
Six-to eight-week-old female wild-type C57BL/6 mice were purchased from the Chinese Academy of Sciences (Shanghai, China). All mice were kept and bred in a specific pathogen-free environment. All animal experiments were conducted in accordance with protocols approved by the Animal Care and Use Committee at Shanghai Medical College, Fudan University. Murine melanoma B16F10 cell line was obtained from the American Type Culture Collection (Manassas, VA). Cells were grown in complete RPMI-1640 media supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin (Gibco, Grand Island, NY, USA).
Animal tumour model
B16F10 cells (5 9 10 5 in 100 ll PBS) were subcutaneously inoculated into the right flanks of C57BL/6 mice, and tumour sizes were measured every 2 days using calipers. The tretinoin ointment (0Á15 g, PanGeo Pharma Inc., Montreal, Canada) or vaseline as control was locally rubbed on the tumour and the skin adjacent to the tumour every day when tumours were palpable. The tumour volume was calculated by the following formula: V = (larger diameter) 9 (smaller diameter) 2 /2.
CD8 + T-cell depletion
Neutralizing anti-mouse CD8a antibody (500 mg, clone YTS169.4; BioXCell, West Lebanon, NH, USA) was injected intraperitoneally into C57BL/6 mice once a week starting from the day when B16F10 cells were inoculated. The control group received the same amount of isotype control antibody (clone LTF2; BioXCell). The efficiency of CD8 + T-cell depletion was determined by flow cytometric analysis of tumour, spleen, lymph nodes and blood (see Supplementary material, Fig. S1 ).
Preparation of single-cell suspension from draining lymph nodes and tumours nylon mesh. Lymph node cells were stimulated with a-CD3 (2 lg/ml, eBioscience, San Diego, CA, USA) for 3 days. The supernatants were harvested for determining the concentrations of IFN-c and tumour necrosis factor-a (TNF-a) using mouse ELISA kits (eBioscience), and cells for flow cytometry. Tumours were collected, cut into pieces and digested by Collagenase IV (1 mg/ml) and DNAase I (5 U/ ml) for 20 min in 37°, and filtered through a 100-lm nylon mesh. A single-cell suspension was used for flow cytometry.
Flow cytometry
After blocking the Fc-receptors with anti-mouse CD16/32 (eBioscience), the following fluorochrome-labelled antimouse antibodies were used: CD45 (30-F11), CD11b (M1/70), Gr-1 (RB6-8C5), F4/80 (BM8), CD4 (GK1. 
RNA isolation and quantitative real-time PCR
Total RNA was extracted using TRIZOL (Ambion, Austin, TX), then cDNA was generated using a high-capacity cDNA Reverse Transcription kit (Takara, Shiga, Japan). Quantitative real-time PCR (qPCR) was performed using an SYBR green Gene Expression Assay (Takara). The data are represented as fold changes of the atRA-treated group compared with the vaseline-treated group. The primer sequences of all genes for PCR were used as followed: Gzmb: 
Cytotoxic T lymphocyte assay
Cytotoxicity was determined by lactate dehydrogenase (LDH) release from B16F10 cells into the culture medium, as LDH is a cytoplasmic enzyme released by dying cells. draining lymph nodes (DLN) cells were prepared from atRA-treated B16F10 tumours, and then incubated with B16F10 cell lysates prepared by a repeated freezethaw process in the presence of interleukin-2 (Peprotech, 10 ng/ml) for 5 days. B16F10 (target cells) cells treated with or without atRA were seeded in 96-well plates as target cells for DLN cells (effector cells) at the effector : target (E : T) ratio of 50 : 1 and 100 : 1 for 5 hr, and then supernatants were collected for the measurement of LDH cytotoxicity activity according to the manufacturer's instructions of the LDH Cytotoxicity Assay Kit (Beyotime, Shanghai, China). DLN cells or B16F10 cells alone were set up as controls for spontaneous LDH release. Maximum LDH release of target cells was determined by lysing B16F10 cells for 1 hr with the lysis buffer provided by the assay kit. The killing rates were calculated using the following formula: killing rates = [(experimental release À target spontaneously release À effector spontaneously release group)/(target maximum release À target spontaneously release)] 9 100.
Statistical analysis
The comparisons between two groups were performed by two-tailed Student's t-tests. Multiple-group comparisons were performed by two-way analysis of variance. The statistical analysis was performed with GRAPHPAD PRISM 6 (GraphPad Software, Inc., San Diego, CA). Significant difference was defined as P < 0Á05.
Results
Topical treatment with atRA suppresses B16F10 tumour growth
We first attempted to examine whether topical treatment with atRA was able to influence the murine melanoma growth. Briefly, tretinoin ointment with atRA as the active ingredient or vaseline as control was locally rubbed on the tumour and the skin adjacent to the tumour every day when tumours were palpable on day 4 after subcutaneous inoculation of B16F10 melanoma cells, and mice were killed on day 14 ( Fig. 1a) . We found that atRA treatment significantly slowed down B16F10 tumour growth ( Fig. 1b) and reduced the volume and weight of B16F10 tumours ( Fig. 1b-d) , demonstrating a therapeutic effect of topical treatment with atRA on murine melanoma.
Topical treatment with atRA causes a pronounced CD8 + T-cell response in the tumour microenvironment Given the immunogenic property of melanoma and the immunoregulatory role of atRA, we next investigated whether topical treatment with atRA influenced the type and the activation of immune cells in tumour sites. Significantly increased frequency of CD45 + leucocytes was observed in atRA-treated B16F10 tumours compared with those treated with vaseline by flow cytometric analysis of enzymatically dissociated cell suspensions (Fig. 2a) . Further analysis revealed that atRA treatment significantly increased the frequency of tumour-infiltrating CD8 + T cells, but not CD4 + T cells, in atRA-treated mice compared with control mice (Fig. 2b) . Moreover, there were significant decreases in the frequencies of tumour-infiltrating MDSCs (CD11b + Gr-1 + ) and macrophages (CD11b + F4/80 + Gr-1 À ) in atRA-treated mice (Fig. 2c) . Importantly, atRA treatment significantly increased the ratios of tumour-infiltrating CD8 + T cells to MDSCs or macrophages (Fig. 2d) , suggesting an enhanced antitumour immune response in the tumour microenvironment.
Furthermore, atRA treatment significantly increased gene expression of several important anti-tumour effector molecules including granzyme B, perforin and IFN-c, which are primarily expressed by activated CD8 + T cells. There was a significant increase in gene expression of chemokines that are important for T-cell migration, including CXCL9 and CXCL10, whereas there was a significant decrease in those that are important for tumour recruitment of MDSCs, including CXCL1, CXCL2 and CCL2, in atRA-treated B16F10 tumours compared with those treated with vaseline (Fig. 2e, f) . This is consistent with the changes in the composition of immune cells upon atRA treatment. Taken together, these results demonstrate that topical treatment with atRA changes the balance between pro-and anti-tumour immune responses in the tumour microenvironment, skewing toward antitumour CD8 + T-cell immunity.
Topical treatment with atRA promotes the activation and proliferation of anti-tumour CD8 + T cells
We next investigated whether topical treatment with atRA activated effector CD8 + T cells in tumour sites. The portions of CD8 + T cells expressing granzyme B, TNF-a or IFN-c, which are closely related to the cytotoxic activities, significantly increased in atRA-treated B16F10 tumour compared with controls (Fig. 3a) . Moreover, atRA treatment significantly enhanced the proliferation of CD8 + T cells, as evidenced by much higher frequency of Ki67 + proliferating CD8 + T cells in atRA-treated B16F10 tumours (Fig. 3b) . In contrast, comparable frequencies of (Fig. 3c ). These results demonstrate that atRA treatment favourably promotes a robust effector CD8 + T-cell response in the tumour microenvironment.
Topical treatment with atRA promotes the differentiation of effector CD8 + T cells in DLN of B16F10 tumour-bearing mice
AtRA is well-known as a differentiation factor in developmental biology, and accumulating data demonstrate the role of atRA in determining T-cell differentiation under homeostatic or inflammatory conditions. 9 We then asked whether topical treatment with atRA influenced T-cell differentiation in B16F10 tumour-bearing mice. To this end, DLN were collected from tumour-bearing mice on day 7 when the tumour size was similar between atRAtreated and vaseline-treated mice to avoid the influence of the size of tumour on T-cell immunity. Greatly elevated concentrations of TNF-a and IFN-c were detected in the cultures of DLN cells of atRA-treated mice compared with those of vaseline-treated mice upon a-CD3 stimulation (Fig. 4a) . Furthermore, there were significant increases in the portions of CD8 + T expressing granzyme B, TNF-a or IFN-c in a-CD3-stimulated DLN cells of atRA-treated mice (Fig. 4b) . In contrast, significantly decreased portion of IFN-c-expressing CD4 + T cells was detected in a-CD3-stimulated DLN cells from atRA-treated mice (Fig. 4c) . Taken together, these results demonstrate that topical treatment with atRA promotes the differentiation of effector CD8 + T cells in DLN of B16F10 melanoma-bearing mice. 
Depletion of CD8 + T cells greatly impairs the melanoma-inhibitory effect of atRA
We then investigated the role of CD8 + T cells in the melanoma-inhibitory effect of atRA by depleting CD8 + T cells in atRA-treated melanoma-bearing mice. CD8 + T-cell depletion significantly impaired the tumour-inhibiting effect of atRA, as evidenced by significant increases in the tumour volume and weight in mice treated with neutralizing anti-CD8 antibody compared with those with isotype antibody (Fig. 5a-c) . However, atRA treatment still significantly decreased the tumour volume and weight of CD8 + T-cell-depleted mice (Fig. 5a-c) , suggesting that both CD8 + T-cell-dependent and T-cell-independent mechanisms mediate the melanoma-inhibitory effect of atRA. Consistently, depletion of CD8 + T cells drastically reduced gene expression of granzyme, perforin and IFN-c (Fig. 5d) , underscoring that CD8 + T cells are the primary source of these molecules in our model. Interestingly, significantly decreased frequency of CD4 + T cells was detected in tumours of atRA-treated mice with neutralizing anti-CD8 antibody compared with those with isotype antibody (Fig. 5e) . Significantly increased MDSCs and macrophages were detected in tumours of atRA-treated mice with CD8 + T-cell depletion (Fig. 5e ). CD8 + T-cell depletion had no effect on gene expression of CXCL1, CXCL2 and CCL2 in tumours of atRA-treated mice (Fig. 5d) . Taken together, these results demonstrate that the therapeutic effect of atRA is partly dependent on CD8 + T cells in our model.
AtRA directly enhances the cytotoxic activity of effector CD8 + T cells by up-regulating MHCI expression in melanoma cells
We next attempted to determine the possible mechanism by which atRA promoted anti-tumour CD8 + T-cell responses. Since CD8 + T-cell-mediated cytotoxicity is MHC class I restricted, we evaluated whether atRA treatment altered the expression of MHCI on B16F10 cells. AtRA treatment significantly up-regulated MHCI expression in CD45
À CD31 À cells, the majority of which were B16F10 cells, from enzymatically dissociated B16F10 melanoma tumours (Fig. 6a, b) . Consistently, in vitro treatment of B16F10 cells with atRA up-regulated MHCI expression in a dose-dependent manner (Fig. 6c) . AtRA at only 10 lM could lead to cytotoxicity as evidenced by significantly increased apoptotic B16F10 cells (see Supplementary material, Fig. S2 ). Interferon-c is well-known to to n = 7 per group). *P < 0Á05, **P < 0Á01, ***p < 0Á001, NS = no significance. Similar results were obtained from three independent experiments.
increase MHCI expression. We therefore examined whether atRA treatment could amplify the promotingeffect of IFN-c on B16F10 cells. As expected, IFN-c significantly increased MHCI expression on B16F10 cells (Fig. 6c) . The addition of atRA could further increase the MHCI expression on B16F10 cells (Fig. 6c) . To determine whether up-regulated MHCI expression on B16F10 cells enhanced the ability of CD8 + T cells to kill these cells, the cytotoxicity assay were performed by co-culturing DLN cells of the tumour-bearing mice and B16F10 cells treated with atRA or DMSO at different ratios. We demonstrated that DLN cells co-cultured with atRA-treated B16F10 cells had significantly higher killing rates than those with DMSO-treated B16F10 cells (Fig. 6d) . These results show that atRA directly up-regulates MHCI expression on B16F10 cells, thereby rendering them sensitive to CD8 + T-cell-mediated killing.
Discussion
We here demonstrate that topical application of atRA effectively inhibits B16F10 tumour growth, which is accompanied by pronounced CD8 + T-cell responses in tumour sites and DLN. Furthermore, we reveal that the therapeutic effect of atRA is partly dependent on CD8 + T cells, as depletion of CD8 + T cells partly restored B16F10 tumour growth in atRA-treated mice. Moreover, our in vitro study reveals that atRA is able to up-regulate MHCI expression in B16F10 cells in a dose-dependent manner, which in turn enhances the cytotoxic activity of CD8 + T cells, while atRA at higher concentrations also enhances the apoptosis of B16F10 cells.
The beneficial role of atRA in melanoma is implicated by a recent finding that vitamin A supplementation could decrease the risk of melanoma in humans. We here demonstrated the therapeutic effect of topical application of atRA on murine B16F10 melanoma. Considering the profound effects of atRA on immune cells, particularly T cells, and the relatively high sensitivity of melanoma to immunotherapy, the melanoma-inhibitory effect of atRA observed in our study was probably due to its immunoregulatory functions. We found that topical treatment with atRA markedly increased the frequency of leucocytes in B16F10 tumour, which was primarily attributed to increased tumour-infiltrating CD8 + T cells. 32 This could be due to the different effects of atRA on CD4 + T cells in physiological or pharmacological concentrations. Notably, in addition to elevated CD8 + T-cell response in tumour sites, topical treatment with atRA could enhance effector CD8 + T-cell differentiation, as significantly increased effector CD8 + T cells expressing granzyme B, TNF-a or IFN-c were detected in DLN of tumour-bearing mice on day 7 after B16F10 cell inoculation. This is supported by previous studies showing that administration of atRA provides protection against infection by promoting the differentiation of effector CD8 + T cells. 15 In contrast, there was significantly decreased IFN-c-expressing CD4 + T cells in DLN of atRA-treated mice, which is consistent with the previous findings that exogenous atRA inhibited IFN-c production during the early phase of Th1 differentiation. 33 Collectively, these results indicate that topical treatment with exogenous atRA promotes a robust CD8 + T-cell response, which could contribute to the inhibition of B16F10 melanoma. We further confirmed the requirement of CD8 + T cells for the melanoma-inhibiting effect of atRA by showing that depletion of CD8 + T cells restored B16F10 tumour growth in atRA-treated mice. However, atRA treatment still had the inhibitory effect on B16F10 tumour growth in the absence of CD8 + T cells, suggesting the existence of a CD8 + T-cell-independent mechanism. Natural killer (NK) cells were reported to be in synergy with CD8 + T cells to inhibit established B16F10 tumour. 34 However, we found that topical treatment with atRA had no effect on the frequency of NK cells and IFN-c-expressing NK cells in B16F10 tumours regardless of the presence of CD8 + T cells (see Supplementary material, Fig. S3b ), which excluded the possibility that NK cells mediate the therapeutic effect of atRA on established B16F10 tumour. AtRA can induce apoptosis of many types of cancer cells including melanoma at high non-physiological concentrations. 25, 35 Consistently, we found that atRA at higher concentration (10 lM) could significantly induce the apoptosis of B16F10 cells, suggesting that the direct pro-apoptotic effect of atRA on melanoma cells may also contribute to the inhibition of B16F10 tumour growth in vivo.
Early studies have demonstrated that MHCI is a direct transcriptional target of atRA. 36, 37 A recent study also demonstrated that the therapeutic effect of atRA on murine colon cancer is dependent on its ability to directly up-regulate MHCI expression in tumour epithelial cells, thereby rendering them susceptible to CD8 + T-cell-mediated killing. 38 We also found that atRA treatment could up-regulate MHCI expression in B16F10 cells that are not transformed from epithelial cells in a dose-dependent manner. Furthermore, atRA could further amplify the ability of IFN-c to up-regulate MHCI expression in B16F10 cells. More importantly, we demonstrated that DLN cells from tumourbearing mice exhibited a significantly higher killing ability when cultured with atRA-treated B16F10 cells. These results indicate that topical treatment with atRA could up-regulate MHCI expression in B16F10 cells, which in turn makes them a better target of CD8 + cytotoxic Tcell killing. 
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